Myeloma: Real-World Use of Bispecific Antibodies in Community Oncology | Lisa Herms, PhD | #ASH24

KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24

Side Effect Severity & Decision-Making Autonomy in Myeloma | Jay Hydren, PhD, CSCS | #ASH24

Myeloma Patient Experiences with Talquetamab | Jay Hydren, PhD, CSCS | #ASH24

Myeloma Updates: High-Risk Smoldering, MRD, IVIG, and Maintenance | Natalie Callander, MD | #ASH24

Achieving MRD Negativity: Iberdomide Study for Myeloma Post-AHCT | Natalie Callander, MD | #ASH24

Study Shows Promise for Non-Invasive MRD Testing for Myeloma Patients | Dory Abelman PhD(c) | #ASH24

Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24

Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24

Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24

Positive Loncastuximab & Rituximab Results in R/R Follicular Lymphoma | Juan Alderuccio, MD | #ASH24

Treatment Outcomes for LBCL with Central Nervous System Involvement | Juan Alderuccio, MD | #ASH24

Venetoclax + Pola-R-CHP for High-Risk B-Cell Lymphoma | Catherine Diefenbach, MD | #ASH24

Glofit-R-ICE for Patients with Relapsed/Refractory DLBCL | Catherine Diefenbach, MD | #ASH24

Bispecific Antibody Use After CAR-T Failure for B-Cell Lymphoma | Megan Melody, MD, MS | #ASH24

Safety of CAR-T Therapy, Tisa-cel, for DLBCL | Christian Chabannon, MD, PhD | #ASH24

Moving the Diffuse Large B-Cell Lymphoma Field Forward | Matthew Matasar, MD | #ASH24

Safety & Efficacy of Odronextamab for DLBCL After CAR-T Failure | Matthew Matasar, MD | #ASH24

Ketogenic Diet During CAR-T Therapy for DLBCL | Christopher D'Angelo, MD | #ASH24

Boom-Boom Radiation as Bridging Therapy Prior to CAR-T for DLBCL | Christopher D'Angelo, MD | #ASH24

Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD |#ASH24

Gamma Secretase Inhibition May Boost CAR-T Effectiveness in Some Myeloma | Andrew Portugese | #ASH24

Who is typically prescribed JAK2 inhibitors?

What is smoldering (asymptomatic) multiple myeloma?